Use of nilotinib for the preparation of a medicament for inhibiting the p53-AKT interaction
By using nilotinib to block the interaction between p53 and AKT, the problem of the inability to effectively target and block p53-AKT in existing technologies has been solved, thus overcoming chemotherapy resistance and enhancing the efficacy of chemotherapy in various tumor cells.
CN122140715APending Publication Date: 2026-06-05SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
- Filing Date
- 2026-02-26
- Publication Date
- 2026-06-05
Smart Images
Figure CN122140715A_ABST
Abstract
The application relates to the technical field of biological medicine, and discloses application of Nilotinib in preparation of a drug for inhibiting p53-AKT interaction. Relying on a double-fluorescence reporting system NanoBRET system, high-throughput screening is completed at a live cell level, and it is determined that a tyrosine kinase inhibitor Nilotinib can inhibit p53-AKT interaction. Function verification shows that Nilotinib can dose-dependently destroy a p53-AKT complex in HEK293T tool cells and U87MG, T98G and other glioma cells, release the inhibition of p53 function, and induce cell apoptosis. The above results illustrate a new path of precise intervention with the "p53-AKT interface" as a target, and provide experimental basis for redirecting Nilotinib to overcome p53-related drug resistance.
Need to check novelty before this filing date? Find Prior Art